Robert Charles Swanton

Title: The Innovative Contributions of Robert Charles Swanton

Introduction

Robert Charles Swanton is a prominent inventor based in London, GB. He has made significant contributions to the field of cancer research through his innovative patents. With a total of 3 patents, Swanton's work focuses on improving cancer detection and prognosis.

Latest Patents

One of his latest patents is a method of detecting tumour recurrence. This invention relates to subject-specific methods for detecting recurrence of tumours based on an understanding of the clonal/subclonal mutation profile of the subject's tumour. It involves the detection of mutations in their cell-free DNA (cfDNA), typically by multiplex PCR of tumour mutations such as single nucleotide variants (SNVs). Another notable patent is a method of predicting survival rates for cancer patients. This method provides a prognosis for a subject with lung cancer by contacting a biological sample from the subject with reagents that specifically bind to a panel of biomarkers. The process includes determining a risk score based on the nucleic acid levels of expression of the biomarkers in the samples and providing a prognosis based on that risk score.

Career Highlights

Throughout his career, Swanton has worked with notable companies such as Natera, Inc. and The Francis Crick Institute Limited. His work in these organizations has allowed him to further his research and contribute to advancements in cancer treatment and detection.

Collaborations

Swanton has collaborated with esteemed colleagues, including Christopher Abbosh and Bernhard Zimmermann. These collaborations have enhanced his research efforts and have been instrumental in the development of his innovative patents.

Conclusion

Robert Charles Swanton's contributions to cancer research through his patents demonstrate his commitment to improving patient outcomes. His innovative methods for detecting tumour recurrence and predicting survival rates are significant advancements in the field.